ABSTRACT
Rapid and accurate diagnosis of Chronic Obstructive Pulmonary Disease (COPD) is problematic in acute-care settings, particularly in the presence of infective comorbidities. The aim of this study was to develop a rapid, smartphone-based algorithm for the detection of COPD, in the presence or absence of acute respiratory infection, and then evaluate diagnostic accuracy on an independent validation set.
Subjects aged 40-75 years with or without symptoms of respiratory disease who had no chronic respiratory condition apart from COPD, chronic bronchitis or emphysema, were recruited into the study. The algorithm analysed five cough sounds and four patient-reported clinical symptoms providing a diagnosis in less than one minute. Clinical diagnoses were determined by a specialist physician using all available case notes, including spirometry where available.
The algorithm demonstrated high percent agreement (PA) with reference clinical diagnosis for COPD in the total cohort (n=252, Positive PA=93.8%, Negative PA=77.0%, AUC=0.95); in subjects with pneumonia or infective exacerbations of COPD (n=117, PPA=86.7%, NPA=80.5%, AUC=0.93) and in subjects without an infective comorbidity (n=135, PPA=100.0%, NPA=74.0%, AUC=0.97.) In those who had their COPD confirmed by spirometry (n=229), PPA = 100.0% and NPA = 77.0%, AUC=0.97.
The algorithm demonstrates high agreement with clinical diagnosis and rapidly detects COPD in subjects presenting with or without other infective lung illnesses. The algorithm can be installed on a smartphone to provide bedside diagnosis of COPD in acute care settings, inform treatment regimens and identify those at increased risk of mortality due to seasonal or other respiratory ailments.
Competing Interest Statement
PP, SC and UA are scientific advisors in ResApp Health (RAP). PP and UA are shareholders in RAP. UA was RAP's Chief Scientist. RAP is an Australian publicly listed company commercialising the technology under license from the University of Queensland, where UA is employed. UA is a named inventor of the UQ technology. VS and JW are employees of ResApp Health. NB, JB, CS, and PD declare no competing interests.
Clinical Trial
ACTRN12618001521213
Funding Statement
ResApp Health provided funding to support the Breathe Easy Program at JHC and UQ. Joondalup Health Campus provided office space, IT services and consumables in kind.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Human Research Ethics Committees of Princess Margaret Hospital (2015030EP), Joondalup Health Campus (1501), Curtin University (HRE2018 0016) and The University of Queensland (2015000395 2016.01.179).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The underlying codes are the property of ResApp Health and are not available. The datasets supporting the conclusion of this article are available on reasonable request from PP and JB. The cough recordings are not available but will be uploaded as an educational tool in the future.
